Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Pricing Drug Safety Clinical Trials Weight Loss Weight Loss Drugs Cancer Treatment Drug Regulation Medications

Novo’s CagriSema Misses Non-Inferiority to Lilly’s Tirzepatide in 84-Week Head-to-Head Trial

Investor worries deepened, with Novo pointing to a late-2026 FDA decision alongside new trials to clarify the drug’s potential.

FDA Unveils ‘Plausible Mechanism’ Pathway for Individualized Gene and RNA Therapies

ImmunityBio Shares Rise on ANKTIVA Surge, Saudi Approval for Lung Cancer

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Eli Lilly Rolls Out Monthlong Zepbound KwikPen on LillyDirect After FDA OK

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

New Single-Particle Assay Finds Disordered Lipid Nanoparticles Release RNA More Effectively

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I in Adults

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

Telix Confirms Webcast Investor Sessions at Oppenheimer and TD Cowen Conferences

TrumpRX.gov Launches With 40+ Lower-Priced Drugs as Companies Announce Cuts

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

FDA Reverses Course To Review Moderna’s mRNA Flu Shot Under Split Pathway

FDA Sets Single-Study Default for New Drug Approvals

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

Merck and Mayo Clinic Launch AI Drug Discovery Collaboration Using Platform_Orchestrate

Mereo BioPharma Investors Face April 6 Deadline in Lawsuits Over Failed Setrusumab Trials

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

FDA Rejects Filing of Moderna’s mRNA Flu Vaccine Over Comparator Dispute

Democratic Report Puts TrumpRx Under Fresh Scrutiny as Analyses Question Real-World Savings